Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for treatment of hospitalized patients with COVID-19
IRCT20191104045328N7Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Aug 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Colchicine + standard treatment with Placebo + standard treatment (2 arms). Primary endpoints: Duration of hospitalization, Complete blood cell count and 11 more. Started Aug 2021; status: completed.
02
Drugs
colchicine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20191104045328N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191104045328N7.